Log inSign up
Log inSign up
Absci
573 posts
Absci profile banner
@abscibio

Absci

@abscibio
Unlocking differentiated biology with generative AI
Vancouver, WA
absci.com
Joined September 2013
648 Following
3,719 Followers
RepliesRepliesRepostsRepostsMediaMedia

Log in or sign up for X

See what’s happening and join the conversation

Continue with phone
or
Log in with username or email
Terms·Privacy·Cookies·Accessibility·US TIDA·Ads Info·© 2026 X Corp.
  • Pinned
    @abscibio
    Absci
    @abscibio
    Sep 2
    Fierce Biotech (@FierceBiotech) recently sat down with Absci's Founder and CEO @SeanRMcClain and CMO Ransi Somaratne, M.D., to talk about Absci's journey — from its start in a basement in Portland to our plan for a "direct-to-consumer model baked in from the start" because
    Absci headquarters in Vancouver, Washington
    From his parents’ basement to your medicine cabinet: Absci CEO endeavors to create biotech’s Apple
    From fiercebiotech.com
    1
  • @abscibio
    Absci
    @abscibio
    Oct 2
    As part of our commitment to advancing women's health, Absci recently announced key design details for our planned Phase 2 STORYLINE™ clinical trial evaluating ABS-201, an AI-designed therapeutic with the potential to offer a novel, non-sex-hormonal approach to treating
    GIF
  • @abscibio
    Absci
    @abscibio
    Sep 23
    Absci Founder & CEO @SeanRMcClain recently sat down for a podcast interview with hair science educator Rob English, where they break down the potentially regenerative mechanism behind ABS-201 for pattern hair loss. In this video, Sean unpacks the novel science and clinical
    Prolactin Is THE Root Cause of Hair Loss?! Absci’s New Drug May Prove It
    From youtube.com
  • @abscibio
    Absci
    @abscibio
    Sep 1
    Our ABS-201 program were recently featured in @Bloomberg in a segment on innovation in the treatment of hair loss. ABS-201 is our investigational, AI-designed anti-PRLR antibody being evaluated as a potential best-in-class therapeutic for pattern hair loss. ⚫ABS-201 is
    Forget GLP-1 Stocks, Baldness Drugs Are Wall Street’s Next Goldmine
    From bloomberg.com
    2
  • @abscibio
    Absci
    @abscibio
    Aug 14
    Dermatology Times (@DermTimesNow) recently highlighted our lead candidate, ABS-201, in treating pattern hair loss. The interim results from our Phase 1/2a clinical trial underscore the potential of ABS-201 by demonstrating a favorable preliminary safety profile and encouraging
    dermatologytimes.com
    Interim Trial Results and Preclinical Data Highlight Potential of ABS-201 in Androgenetic Alopecia...
    Absci's ABS-201 posts early phase 1 safety and long half-life, while new data show prolactin-receptor blockade may revive hair growth in AGA.